ENTASIS THERAPEUTICS
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).
ENTASIS THERAPEUTICS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.entasistx.com
Total Employee:
11+
Status:
Active
Contact:
(781)810-0120
Email Addresses:
[email protected]
Total Funding:
199.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Font Awesome
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Celsius Therapeutics
Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.
Centerline Biomedical
Centerline Biomedical, a Cleveland Clinic spin-off, is developing an innovative system
Cortexyme
Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Enlibrium
Enlibrium is a developing novel drugs
IMTherapeutics
IM Therapeutics develops personalized immuno-therapeutic drugs.
Phyla
Phyla is developing alternative therapies for antibiotics.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Vico Therapeutics
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
CARB-X
CARB-X investment in Grant - Entasis Therapeutics
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series B - Entasis Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series B - Entasis Therapeutics
TPG
TPG investment in Series B - Entasis Therapeutics
CARB-X
CARB-X investment in Grant - Entasis Therapeutics
Eventide
Eventide investment in Series B - Entasis Therapeutics
Clarus Ventures
Clarus Ventures investment in Series B - Entasis Therapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series B - Entasis Therapeutics
Novo Holdings
Novo Holdings investment in Series B - Entasis Therapeutics
Official Site Inspections
http://www.entasistx.com Semrush global rank: 4.54 M Semrush visits lastest month: 2.31 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Entasis Therapeutics"
Entasis Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number (781)810-0120 Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions …See details»
Entasis Therapeutics Information - RocketReach
Entasis Therapeutics, a subsidiary of Innoviva, Inc., is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of …See details»
Entasis Therapeutics - Devex
Focused on next generation antibacterial therapeutics. Our Story Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights …See details»
Entasis Therapeutics - LinkedIn
Entasis Therapeutics, a subsidiary of Innoviva, Inc., is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of ...See details»
Entasis Therapeutics Holdings Inc. - AnnualReports.com
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat …See details»
Entasis Therapeutics - Company Profile & Staff Directory
Entasis Therapeutics, a subsidiary of Innoviva, Inc., is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of …See details»
Entasis Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Www.entasistx.com. Subsidiary Company | 2015 | Massachusetts, United States | 50-100 | NASDAQ: ETTX | www.entasistx.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. ...See details»
Entasis Therapeutics - Company Profile - Tracxn
Dec 15, 2024 Developer of a portfolio of cures for serious drug-resistant bacterial infections. The company is developing small molecules to treat serious multidrug-resistant Gram-negative …See details»
Entasis Therapeutics - Craft
Jul 11, 2022 Entasis Therapeutics has 3 employees at their 1 location and $7 m in annual revenue in FY 2019. See insights on Entasis Therapeutics including office locations, …See details»
Entasis Therapeutics - Overview, News & Similar companies
Jul 11, 2022 Entasis Therapeutics contact info: Phone number: (781) 810-0120 Website: www.entasistx.com What does Entasis Therapeutics do? Entasis is a late-stage clinical …See details»
Entasis Therapeutics Company Profile -Sales, Contacts, …
Entasis Therapeutics is in the Biotechnical Research, Commercial industry within the Engineering, Accounting, Research, and Management Services sector and has been in business for …See details»
Entasis Therapeutics Management Team | Org Chart
Entasistx.com; comcast.net; 4 860434XXXX; 781228XXXX; 781810XXXX; 860304XXXX; View Similar People. Related Companies VFP Pharmacy Group. 75 $13m connectRN. 662 $44m …See details»
Entasis - VentureRadar
Entasis' anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting …See details»
Entasis Therapeutics Holdings Inc. in Waltham, MA - (781) 810-0120
Entasis Therapeutics Holdings Inc. is in the Pharmaceutical Preparations business. View competitors, revenue, employees, website and phone number.See details»
Entasis Therapeutics Holdings Overview | Salary.com
Discover essential details about Entasis Therapeutics Holdings, including address, contact, and journey of our company's evolution.See details»
Entasis Therapeutics Completes Initial Closing of $20M Private ...
May 3, 2021 Company ContactKyle Dow Entasis Therapeutics (781) 810-0114 [email protected] Investor Relations ContactsJames SaliernoThe Ruth Group(646) …See details»
Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual ...
For more information, visit www.entasistx.com. Entasis Contacts Company: Kyle Dow Entasis Therapeutics (781) 810-0114 [email protected] Investor Relations: Bruce Mackle …See details»
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, …
Oct 19, 2022 Entasis Therapeutics Holdings Inc.--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological EndpointsSee details»
Entasis Therapeutics Introduces ETX0462, a First-in-Class …
WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and …See details»
ETX-0462 - Drug Targets, Indications, Patents - Synapse
Originator Organization. Entasis Therapeutics Holdings, Inc. Active Organization. Combating Antibiotic Resistant Bacteria Accelerator Entasis ... [email protected] Media …See details»